ABSTRACT
We sought to determine whether nuchal translucency (NT) thickness of ≥ 2 mm poses a risk for adverse perinatal outcome. A prospective observational study was conducted including all singleton pregnancies undergoing NT screening between 11 and 13.6 weeks' gestation, from January 1999 to October 2006, in a University Medical Center. Aneuploid and malformed fetuses were excluded from the analysis, as well as fetuses from pregnancies that ended before 22 gestational weeks. A comparison was performed between fetuses with NT of ≥ 2 mm and those with NT < 2 mm. Stratified analyses using the Mantel-Haenszel technique and multivariable analyses were performed to control for confounders. A total of 2205 singleton fetuses with normal karyotype were evaluated during the study period. Of these, 2.0% (n = 45) had NT of 2 mm and above. Pregnancies with NT of ≥ 2 mm were significantly associated with diabetes mellitus (either gestational or pregestational; odds ratio [OR] = 2.3, 95% confidence interval [CI] 1.02 to 5.1; p = 0.023). Higher rates of perinatal mortality (OR = 17.5, 95% CI 4.5 to 61.8; p < 0.001) and stillbirth in particular (OR = 25.6, 95% CI 4.9 to 120.7; p < 0.001) were noted among pregnancies with NT ≥ 2 mm. Using a multivariable analysis and controlling for confounders such as diabetes mellitus and the crown-rump length, NT ≥ 2 mm was found to be an independent risk factor for perinatal mortality (adjusted OR 14.3; 95% CI 1.8 to 3.5; p < 0.001). Nuchal translucency thickness of ≥ 2 mm in euploid, anatomically normal fetuses poses a significant risk for adverse perinatal outcome.
KEYWORDS
Nuchal translucency - ultrasound - perinatal mortality - diabetes mellitus - obstetric outcomes
REFERENCES
-
1
Nicolaides K H, Azar G, Byrne D, Mansur C, Marks K.
Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy.
BMJ.
1992;
304
867-869
-
2
Snijders R J, Noble P, Sebire N, Souka A, Nicolaides K H.
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
Lancet.
1998;
352
343-346
-
3
Snijders R J, Sundberg K, Holzgreve W, Henry G, Nicolaides K H.
Maternal age- and gestation-specific risk for trisomy 21.
Ultrasound Obstet Gynecol.
1999;
13
167-170
-
4
Nicolaides K H.
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Am J Obstet Gynecol.
2004;
191
45-67
-
5
Souka A P, Snijders R J, Novakov A, Soares W, Nicolaides K H.
Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10–14 weeks of gestation.
Ultrasound Obstet Gynecol.
1998;
11
391-400
-
6
Souka A P, Von Kaisenberg C S, Hyett J A, Sonek J D, Nicolaides K H.
Increased nuchal translucency with normal karyotype.
Am J Obstet Gynecol.
2005;
192
1005-1021
-
7
Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides K H.
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10–14 weeks of gestation: population based cohort study.
BMJ.
1999;
318
81-85
-
8
Sherod C, Sebire N J, Soares W, Snijders R J, Nicolaides K H.
Prenatal diagnosis of trisomy 18 at the 10–14-week ultrasound scan.
Ultrasound Obstet Gynecol.
1997;
10
387-390
-
9
Pandya P P, Snijders R J, Johnson S P, De Lourdes Brizot M, Nicolaides K H.
Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation.
Br J Obstet Gynaecol.
1995;
102
957-962
-
10
Maymon R, Jauniaux E, Cohen O, Dreazen E, Weinraub Z, Herman A.
Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency.
Hum Reprod.
2000;
15
2023-2027
-
11
Kagan K O, Avgidou K, Molina F S, Gajewska K, Nicolaides K H.
Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Obstet Gynecol.
2006;
107
6-10
-
12
Comstock C H, Malone F D, Ball R H et al..
Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening?.
Am J Obstet Gynecol.
2006;
195
843-847
-
13
Westin M, Saltvedt S, Almstrom H, Grunewald C, Valentin L.
By how much does increased nuchal translucency increase the risk of adverse pregnancy outcome in chromosomally normal fetuses? A study of 16,260 fetuses derived from an unselected pregnant population.
Ultrasound Obstet Gynecol.
2007;
29
150-158
-
14
Zoppi M A, Ibba R M, Floris M, Manca F, Axiana C, Monni G.
Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses.
BJOG.
2003;
110
584-588
-
15
Michailidis G D, Economides D L.
Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses.
Ultrasound Obstet Gynecol.
2001;
17
102-105
-
16
Hiippala A, Eronen M, Taipale P, Salonen R, Hiilesmaa V.
Fetal nuchal translucency and normal chromosomes: a long-term follow-up study.
Ultrasound Obstet Gynecol.
2001;
18
18-22
-
17
Senat M V, De Keersmaecker B, Audibert F, Montcharmont G, Frydman R, Ville Y.
Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype.
Prenat Diagn.
2002;
22
345-349
-
18
Leipold H, Worda C, Ozbal A, Husslein P, Krampl E.
First-trimester nuchal translucency screening in pregnant women who subsequently developed gestational diabetes.
J Soc Gynecol Investig.
2005;
12
529-532
-
19
Kelekci S, Yilmaz B, Savan K, Sonmez S.
Can increased nuchal translucency in the first trimester of pregnancy predict gestational diabetes mellitus.
J Obstet Gynaecol.
2005;
25
579-582
-
20
Nicolaides K H, Snijders R J, Cuckle H S.
Correct estimation of parameters for ultrasound nuchal translucency screening.
Prenat Diagn.
1998;
18
519-523
-
21
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides K H.
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Prenat Diagn.
2005;
25
927-929
-
22
Nicolaides K H, Heath V, Cicero S.
Increased fetal nuchal translucency at 11–14 weeks.
Prenat Diagn.
2002;
22
308-315
-
23
Haak M C, van Vugt J M.
Pathophysiology of increased nuchal translucency: a review of the literature.
Hum Reprod Update.
2003;
9
175-184
-
24
Plante G E, Chakir M, Ettaouil K, Lehoux S, Sirois P.
Consequences of alteration in capillary permeability.
Can J Physiol Pharmacol.
1996;
74
824-833
-
25
Brausewetter F, Jehle P M, Jung M F et al..
Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF).
Horm Metab Res.
2001;
33
713-720
-
26
Bartha J L, Wood J, Kyle P M, Soothill P W.
The effect of metabolic control on fetal nuchal translucency in women with insulin-dependent diabetes: a preliminary study.
Ultrasound Obstet Gynecol.
2003;
21
451-454
Eyal SheinerM.D.
Departments of Obstetrics and Gynecology, Soroka University Medical Center
Beer-Sheva 84103, Israel
eMail: sheiner@bgu.ac.il
